Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Cholinergic synapse (mmu04725)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
Ache
KLA  ATP  ATP+KLA
 NM_009599 acetylcholinesterase (Ache), mRNA [NM_009599] KLA 1.01 1.02 1.03 1.07 1.03 1.05 1.05
ATP .96 1.02 1.03 1.02 1.10 1.04 1.08
KLA/ATP 1.06 .98 .97 1.04 1.04 1.13 1.12
Adcy1
KLA  ATP  ATP+KLA
 BC050125 adenylate cyclase 1, mRNA (cDNA clone IMAGE:30015692). [BC050125] KLA 1.05 1.03 .98 1.04 1.05 1.09 1.10
ATP .90 1.02 .99 .97 1.03 .95 1.01
KLA/ATP .99 1.04 .90 .98 .98 1.00 1.03
Adcy1
KLA  ATP  ATP+KLA
 NM_009622 adenylate cyclase 1 (Adcy1), mRNA [NM_009622] KLA 1.07 1.02 1.06 1.07 1.03 1.02 1.01
ATP 1.02 1.04 1.00 .99 .99 .95 .97
KLA/ATP .97 1.05 1.02 1.05 1.01 .98 1.05
Adcy2
KLA  ATP  ATP+KLA
 NM_153534 adenylate cyclase 2 (Adcy2), mRNA [NM_153534] KLA .79 .82 .83 .73 .61 .66 .90
ATP 1.10 1.09 1.02 1.04 .88 .58 .53
KLA/ATP .84 .87 .77 .75 .68 .60 .43
Adcy3
KLA  ATP  ATP+KLA
 NM_138305 adenylate cyclase 3 (Adcy3), mRNA [NM_138305] KLA .84 .84 .83 .78 .66 .55 .49
ATP 1.09 1.05 .89 1.02 .84 .62 1.52
KLA/ATP .93 .87 .75 .85 .66 .83 .77
Adcy4
KLA  ATP  ATP+KLA
 NM_080435 adenylate cyclase 4 (Adcy4), mRNA [NM_080435] KLA 1.05 1.07 .96 1.00 1.04 1.05 1.05
ATP 1.02 1.05 1.02 1.48 1.37 1.08 1.09
KLA/ATP 1.00 1.05 .91 1.19 1.35 1.27 1.08
Adcy5
KLA  ATP  ATP+KLA
 NM_001012765 adenylate cyclase 5 (Adcy5), mRNA [NM_001012765] KLA 1.06 1.00 .97 1.01 1.03 .95 .93
ATP .95 1.08 1.08 1.07 .97 1.03 .97
KLA/ATP .97 .92 1.04 .99 .91 .96 1.04
Adcy6
KLA  ATP  ATP+KLA
 NM_007405 adenylate cyclase 6 (Adcy6), mRNA [NM_007405] KLA 1.10 1.16 1.16 1.09 1.08 1.06 .99
ATP 1.05 .97 1.08 1.12 1.08 1.08 1.04
KLA/ATP 1.14 1.20 1.29 1.30 1.25 1.11 1.07
Adcy7
KLA  ATP  ATP+KLA
 NM_001037724 adenylate cyclase 7 (Adcy7), transcript variant 3, mRNA [NM_001037724] KLA .43 .39 .35 .32 .45 .72 .84
ATP .90 .84 .62 .41 .53 .42 .94
KLA/ATP .39 .34 .23 .17 .41 .34 .67
Adcy7
KLA  ATP  ATP+KLA
 NM_007406 adenylate cyclase 7 (Adcy7), transcript variant 1, mRNA [NM_007406] KLA .51 .52 .48 .41 .59 .81 .99
ATP 1.01 1.02 .62 .52 .53 .38 .98
KLA/ATP .53 .48 .30 .27 .42 .36 .65
Adcy8
KLA  ATP  ATP+KLA
 NM_009623 adenylate cyclase 8 (Adcy8), mRNA [NM_009623] KLA 1.00 1.00 1.07 .97 1.04 .98 1.02
ATP 1.04 1.05 1.14 1.03 .99 1.00 .97
KLA/ATP 1.05 1.04 1.00 1.03 .98 .94 .96
Adcy9
KLA  ATP  ATP+KLA
 NM_009624 adenylate cyclase 9 (Adcy9), mRNA [NM_009624] KLA .18 .15 .13 .15 .17 .19 .33
ATP 1.33 1.16 .97 .98 .62 .56 .86
KLA/ATP .19 .16 .17 .18 .20 .25 .38
Akt1
KLA  ATP  ATP+KLA
 NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
 NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
 NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
Atf4
KLA  ATP  ATP+KLA
 NM_009716 activating transcription factor 4 (Atf4), mRNA [NM_009716] KLA .91 1.06 1.13 1.31 1.92 2.59 3.01
ATP 1.05 1.14 1.34 2.88 4.84 2.36 2.56
KLA/ATP 1.14 1.08 1.17 2.40 3.72 3.54 3.62
BB548379
KLA  ATP  ATP+KLA
 BB548379 gb|BB548379 RIKEN full-length enriched, 2 days pregnant adult female oviduct Mus musculus cDNA clone E230007L20 3. [BB548379] KLA .98 1.05 1.00 .99 1.04 1.04 1.05
ATP 1.01 .98 1.01 1.02 .98 1.08 .92
KLA/ATP .98 1.06 1.03 1.03 1.00 1.00 .99
Bcl2
KLA  ATP  ATP+KLA
 NM_009741 B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 1, mRNA [NM_009741] KLA .30 .26 .25 .25 .34 .38 .26
ATP .97 .89 1.50 1.04 .99 .29 .52
KLA/ATP .28 .26 .40 .33 .62 .29 .12
Bcl2
KLA  ATP  ATP+KLA
 NM_177410 B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 2, mRNA [NM_177410] KLA .33 .33 .37 .42 .49 .46 .39
ATP 1.07 1.12 1.22 1.56 1.00 .38 .76
KLA/ATP .35 .34 .54 .89 .76 .36 .23
Cacna1a
KLA  ATP  ATP+KLA
 NM_007578 calcium channel, voltage-dependent, P/Q type, alpha 1A subunit (Cacna1a), mRNA [NM_007578] KLA .71 .66 .61 .63 .60 .71 .72
ATP 1.07 1.04 .89 1.08 .71 .56 .75
KLA/ATP .71 .72 .85 .69 .64 .63 .68
Cacna1b
KLA  ATP  ATP+KLA
 U04999 N-type calcium channel alpha1 subunit mRNA, complete cds [U04999] KLA .94 .94 .95 .88 1.09 .85 .92
ATP 1.06 1.17 1.00 1.24 1.59 1.15 1.17
KLA/ATP .91 .91 .95 .95 .90 .97 1.01
Cacna1d
KLA  ATP  ATP+KLA
 NM_001083616 calcium channel, voltage-dependent, L type, alpha 1D subunit (Cacna1d), transcript variant 2, mRNA [NM_001083616] KLA 1.57 1.58 2.50 3.62 4.55 2.93 .99
ATP 1.12 .99 .97 .94 .75 1.71 1.48
KLA/ATP 1.47 1.51 1.82 1.56 1.67 2.93 4.60
Cacna1d
KLA  ATP  ATP+KLA
 NM_028981 calcium channel, voltage-dependent, L type, alpha 1D subunit (Cacna1d), transcript variant 1, mRNA [NM_028981] KLA 1.20 1.26 1.43 1.62 2.07 1.66 1.00
ATP 1.03 1.03 .97 .97 .93 1.20 1.26
KLA/ATP 1.16 1.12 1.10 1.14 1.08 1.44 2.56
Cacna1f
KLA  ATP  ATP+KLA
 NM_019582 calcium channel, voltage-dependent, alpha 1F subunit (Cacna1f), mRNA [NM_019582] KLA 1.03 .98 1.05 1.06 1.00 1.02 1.01
ATP 1.05 1.05 .95 .98 .97 .96 1.01
KLA/ATP 1.01 1.03 .94 1.01 1.01 1.00 .99
Cacna1s
KLA  ATP  ATP+KLA
 NM_001081023 calcium channel, voltage-dependent, L type, alpha 1S subunit (Cacna1s), mRNA [NM_001081023] KLA 1.03 1.01 .96 1.06 1.00 1.00 1.05
ATP 1.01 .98 1.02 1.02 1.05 1.07 1.05
KLA/ATP .99 1.05 1.02 1.05 1.03 1.05 1.00
Camk2a
KLA  ATP  ATP+KLA
 NM_177407 calcium/calmodulin-dependent protein kinase II alpha (Camk2a), transcript variant 2, mRNA [NM_177407] KLA .98 .97 .98 .95 .97 1.02 .97
ATP .98 1.11 1.02 .89 .94 .89 .82
KLA/ATP .99 .95 1.02 .88 .88 .87 .87
Camk2b
KLA  ATP  ATP+KLA
 NM_007595 calcium/calmodulin-dependent protein kinase II, beta (Camk2b), mRNA [NM_007595] KLA 1.09 1.28 1.42 1.41 1.37 1.24 .68
ATP .94 .87 .95 .91 .67 .44 .48
KLA/ATP 1.16 1.24 1.40 1.13 1.14 .81 .49
Camk2d
KLA  ATP  ATP+KLA
 AK032524 adult male olfactory brain cDNA, RIKEN full-length enriched library, clone:6430579P05 product:calcium/calmodulin-dependent protein kinase II, delta, full insert sequence. [AK032524] KLA 1.31 1.45 1.42 1.21 1.34 1.18 1.16
ATP 1.04 1.29 1.39 1.24 .94 .91 1.22
KLA/ATP 1.46 1.64 1.42 1.24 1.00 .93 1.10
Camk2d
KLA  ATP  ATP+KLA
 NM_001025439 calcium/calmodulin-dependent protein kinase II, delta (Camk2d), transcript variant 1, mRNA [NM_001025439] KLA 1.76 1.75 1.72 1.89 1.47 1.55 1.24
ATP 1.06 1.06 .93 1.01 1.22 .98 2.28
KLA/ATP 1.84 1.78 1.40 1.57 1.07 .60 1.97
Camk2g
KLA  ATP  ATP+KLA
 NM_178597 calcium/calmodulin-dependent protein kinase II gamma (Camk2g), transcript variant 1, mRNA [NM_178597] KLA .23 .24 .23 .44 .70 .73 .70
ATP .91 .85 1.07 .86 .58 .59 .95
KLA/ATP .22 .20 .35 .25 .54 .59 .71
Camk4
KLA  ATP  ATP+KLA
 AK043457 7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730097A20 product:CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE IV CATALYTIC CHAIN (EC 2.7.1.123) (CAM KINASE-GR) (CAMK IV) [CONTAINS: CALSPERMIN] homolog [Mus KLA .98 1.04 1.02 .93 1.03 1.07 1.07
ATP 1.01 .97 .97 1.10 1.00 .99 1.05
KLA/ATP 1.00 .96 1.02 .98 1.13 1.07 1.00
Camk4
KLA  ATP  ATP+KLA
 NM_009793 calcium/calmodulin-dependent protein kinase IV (Camk4), mRNA [NM_009793] KLA .96 1.02 1.01 1.02 1.03 1.07 1.08
ATP 1.01 1.03 1.07 1.08 .99 1.00 .99
KLA/ATP 1.01 .95 .98 1.08 1.12 1.02 1.03
Chat
KLA  ATP  ATP+KLA
 NM_009891 choline acetyltransferase (Chat), mRNA [NM_009891] KLA 1.03 1.02 1.01 1.05 1.03 .96 1.06
ATP .99 1.01 1.03 1.05 1.01 1.00 .99
KLA/ATP 1.02 1.01 1.00 .97 .98 .94 1.03
Chrm1
KLA  ATP  ATP+KLA
 NM_001112697 cholinergic receptor, muscarinic 1, CNS (Chrm1), transcript variant 1, mRNA [NM_001112697] KLA 1.12 .99 .97 1.09 .92 .91 .97
ATP .95 1.06 1.01 1.06 1.05 1.06 .99
KLA/ATP 1.00 .99 1.02 1.00 1.05 .95 1.01
Chrm2
KLA  ATP  ATP+KLA
 NM_203491 cholinergic receptor, muscarinic 2, cardiac (Chrm2), mRNA [NM_203491] KLA 1.03 1.05 .98 1.02 1.04 1.06 1.05
ATP 1.09 .94 1.08 1.06 .98 1.04 .97
KLA/ATP 1.01 1.05 .97 1.01 .98 1.07 .99
Chrm3
KLA  ATP  ATP+KLA
 AK051841 12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230008K23 product:unclassifiable, full insert sequence. [AK051841] KLA .92 .97 1.02 1.05 .96 .99 1.00
ATP 1.00 .99 .99 .95 1.05 1.02 1.01
KLA/ATP .91 .98 1.06 1.07 .94 1.00 .94
Chrm3
KLA  ATP  ATP+KLA
 NM_033269 cholinergic receptor, muscarinic 3, cardiac (Chrm3), mRNA [NM_033269] KLA .91 .99 .98 .93 1.08 1.01 1.06
ATP .97 1.05 1.03 .95 .99 1.01 1.10
KLA/ATP 1.05 1.09 .99 1.00 .98 1.03 1.00
Chrm4
KLA  ATP  ATP+KLA
 NM_007699 cholinergic receptor, muscarinic 4 (Chrm4), mRNA [NM_007699] KLA .95 1.01 .97 .97 .96 1.07 1.04
ATP 1.08 1.01 1.04 1.08 1.01 .99 .98
KLA/ATP 1.01 1.04 1.04 .99 .99 .96 .99
Chrm5
KLA  ATP  ATP+KLA
 NM_205783 cholinergic receptor, muscarinic 5 (Chrm5), mRNA [NM_205783] KLA .98 1.02 .96 .98 1.03 1.02 1.02
ATP 1.02 .96 .96 1.15 1.00 1.06 1.04
KLA/ATP 1.02 .90 .95 1.05 1.04 1.05 .95
Chrna3
KLA  ATP  ATP+KLA
 NM_145129 cholinergic receptor, nicotinic, alpha polypeptide 3 (Chrna3), mRNA [NM_145129] KLA 1.03 1.04 1.00 1.03 1.08 1.04 .99
ATP .98 .95 .97 1.02 1.04 1.02 .99
KLA/ATP .99 .99 1.02 1.04 1.07 .99 1.02
Chrna4
KLA  ATP  ATP+KLA
 NM_015730 cholinergic receptor, nicotinic, alpha polypeptide 4 (Chrna4), mRNA [NM_015730] KLA .99 .96 1.01 1.01 1.00 .98 .96
ATP 1.02 .98 .97 1.04 .94 .96 .94
KLA/ATP .97 .99 1.00 .98 1.00 .98 .98
Chrna6
KLA  ATP  ATP+KLA
 NM_021369 cholinergic receptor, nicotinic, alpha polypeptide 6 (Chrna6), mRNA [NM_021369] KLA 1.05 .98 1.00 .93 1.05 .98 .96
ATP .99 .93 .98 .99 .92 .95 1.01
KLA/ATP 1.00 1.00 1.02 .93 .96 .94 1.05
Chrna7
KLA  ATP  ATP+KLA
 NM_007390 cholinergic receptor, nicotinic, alpha polypeptide 7 (Chrna7), mRNA [NM_007390] KLA 1.01 .99 1.04 .96 .99 .99 1.01
ATP .99 .97 1.00 1.00 .99 1.04 1.00
KLA/ATP .98 1.02 1.04 .99 .95 .96 1.07
Chrnb2
KLA  ATP  ATP+KLA
 NM_009602 cholinergic receptor, nicotinic, beta polypeptide 2 (neuronal) (Chrnb2), mRNA [NM_009602] KLA .89 .85 .89 .88 .78 .97 .93
ATP 1.03 .99 1.36 2.35 1.30 .97 .86
KLA/ATP .86 .91 .80 1.23 1.14 1.03 1.02
Chrnb4
KLA  ATP  ATP+KLA
 NM_148944 cholinergic receptor, nicotinic, beta polypeptide 4 (Chrnb4), mRNA [NM_148944] KLA 1.01 1.04 .94 1.00 1.01 .96 .98
ATP .97 1.00 .98 .98 1.01 1.05 1.00
KLA/ATP .95 .99 1.06 .97 .98 .99 1.04
Creb1
KLA  ATP  ATP+KLA
 NM_009952 cAMP responsive element binding protein 1 (Creb1), transcript variant B, mRNA [NM_009952] KLA 1.42 1.33 1.16 .99 .83 .97 .92
ATP .92 .91 1.18 1.38 1.51 1.02 .75
KLA/ATP 1.34 1.31 1.49 1.37 1.71 1.05 .93
Creb3
KLA  ATP  ATP+KLA
 NM_013497 cAMP responsive element binding protein 3 (Creb3), mRNA [NM_013497] KLA 1.21 1.21 1.23 1.53 1.77 1.77 1.31
ATP 1.02 1.03 .99 1.05 .82 .83 1.48
KLA/ATP 1.15 1.18 1.20 1.26 1.13 1.15 1.86
Creb3l1
KLA  ATP  ATP+KLA
 NM_011957 cAMP responsive element binding protein 3-like 1 (Creb3l1), mRNA [NM_011957] KLA 1.18 1.17 1.53 1.28 1.22 1.11 1.23
ATP 1.01 1.09 .98 1.17 1.22 1.01 1.15
KLA/ATP 1.22 1.29 1.08 1.34 1.14 1.36 1.12
Creb3l2
KLA  ATP  ATP+KLA
 AK082964 12 days embryo spinal cord cDNA, RIKEN full-length enriched library, clone:C530025K05 product:unclassifiable, full insert sequence [AK082964] KLA .44 .38 .37 .40 .45 .42 .47
ATP .90 .78 1.22 .79 .54 .46 .44
KLA/ATP .41 .41 .49 .43 .50 .51 .23
Creb3l2
KLA  ATP  ATP+KLA
 NM_178661 cAMP responsive element binding protein 3-like 2 (Creb3l2), mRNA [NM_178661] KLA .98 .87 .76 .98 1.03 .87 1.12
ATP 1.20 1.18 1.50 1.35 .86 1.32 1.50
KLA/ATP .98 1.04 1.15 1.05 .79 1.27 1.25
Creb3l3
KLA  ATP  ATP+KLA
 NM_145365 cAMP responsive element binding protein 3-like 3 (Creb3l3), mRNA [NM_145365] KLA .66 .75 .65 .85 1.04 1.44 1.73
ATP 1.02 .98 .97 1.09 .85 .69 1.11
KLA/ATP .70 .66 .71 .83 .80 .85 1.05
Creb3l4
KLA  ATP  ATP+KLA
 NM_030080 cAMP responsive element binding protein 3-like 4 (Creb3l4), mRNA [NM_030080] KLA 1.55 1.42 1.51 1.73 1.76 2.54 1.38
ATP 1.07 .81 .89 1.08 .94 1.08 1.08
KLA/ATP 1.44 1.38 1.44 1.25 1.30 1.26 2.24
Creb5
KLA  ATP  ATP+KLA
 AK051306 12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130032G03 product:unclassifiable, full insert sequence. [AK051306] KLA 2.18 2.13 2.42 1.97 1.57 1.94 1.98
ATP 1.11 1.09 1.47 1.74 1.36 1.44 1.62
KLA/ATP 2.55 2.77 3.02 3.15 2.51 2.52 2.61
Creb5
KLA  ATP  ATP+KLA
 NM_172728 cAMP responsive element binding protein 5 (Creb5), mRNA [NM_172728] KLA 3.70 3.60 2.84 2.39 1.92 2.81 1.84
ATP .92 .89 1.19 1.93 1.51 1.55 1.44
KLA/ATP 3.16 3.51 4.33 5.35 5.78 3.23 3.03
Fos
KLA  ATP  ATP+KLA
 NM_010234 FBJ osteosarcoma oncogene (Fos), mRNA [NM_010234] KLA .42 .33 .64 .61 .71 .85 .71
ATP 3.48 5.46 23.78 25.22 1.71 2.36 1.50
KLA/ATP .90 1.74 5.97 8.62 1.28 2.42 4.52
Fyn
KLA  ATP  ATP+KLA
 U70324 Fyn(T) (L-fyn(T)) mRNA, complete cds. [U70324] KLA 1.23 1.27 1.31 1.27 1.31 .87 .48
ATP .88 .71 .66 .75 .90 1.28 .51
KLA/ATP 1.12 1.01 .94 .84 1.25 1.51 .53
Gna11
KLA  ATP  ATP+KLA
 NM_010301 guanine nucleotide binding protein, alpha 11 (Gna11), mRNA [NM_010301] KLA .62 .65 .69 .79 .94 1.00 .96
ATP 1.00 .94 .63 .53 .79 1.13 1.22
KLA/ATP .64 .60 .56 .55 .81 1.16 1.18
Gnai1
KLA  ATP  ATP+KLA
 NM_010305 guanine nucleotide binding protein (G protein), alpha inhibiting 1 (Gnai1), mRNA [NM_010305] KLA .95 1.01 1.01 1.00 1.09 1.10 1.08
ATP 1.06 1.06 .99 1.15 1.02 .94 .99
KLA/ATP 1.02 1.04 .99 1.16 1.01 1.02 1.13
Gnai2
KLA  ATP  ATP+KLA
 NM_008138 guanine nucleotide binding protein (G protein), alpha inhibiting 2 (Gnai2), mRNA [NM_008138] KLA .74 .79 .82 .74 .91 .97 1.10
ATP 1.07 1.16 .78 1.12 .78 .48 .82
KLA/ATP .91 .81 .53 .80 .60 .68 .87
Gnai3
KLA  ATP  ATP+KLA
 NM_010306 guanine nucleotide binding protein (G protein), alpha inhibiting 3 (Gnai3), mRNA [NM_010306] KLA 1.23 1.24 1.14 1.06 .99 1.15 1.09
ATP .96 .93 .86 .64 1.34 2.02 1.35
KLA/ATP 1.20 1.24 .97 .76 1.21 1.62 1.17
Gnao1
KLA  ATP  ATP+KLA
 NM_001113384 guanine nucleotide binding protein, alpha O (Gnao1), transcript variant B, mRNA [NM_001113384] KLA .95 .98 1.03 1.00 1.02 1.02 .99
ATP .95 1.02 1.01 1.08 .99 .97 .95
KLA/ATP 1.05 1.04 1.10 .99 1.01 .98 1.03
Gnao1
KLA  ATP  ATP+KLA
 NM_010308 guanine nucleotide binding protein, alpha O (Gnao1), transcript variant A, mRNA [NM_010308] KLA .98 .96 1.00 .97 .96 .97 1.01
ATP 1.12 .99 1.05 .87 .97 1.02 1.01
KLA/ATP .93 1.00 .99 1.01 1.05 1.07 .98
Gnaq
KLA  ATP  ATP+KLA
 NM_008139 guanine nucleotide binding protein, alpha q polypeptide (Gnaq), mRNA [NM_008139] KLA .82 .82 .69 .64 .60 .55 .55
ATP 1.06 1.02 .87 .67 .50 .66 .57
KLA/ATP .82 .79 .66 .55 .41 .33 .48
Gnb1
KLA  ATP  ATP+KLA
 NM_008142 guanine nucleotide binding protein (G protein), beta 1 (Gnb1), mRNA [NM_008142] KLA 1.11 1.18 1.22 1.19 1.29 1.32 1.76
ATP 1.02 1.09 .84 .99 .97 .89 1.22
KLA/ATP 1.20 1.25 .85 1.01 .86 .91 1.57
Gnb2
KLA  ATP  ATP+KLA
 NM_010312 guanine nucleotide binding protein (G protein), beta 2 (Gnb2), mRNA [NM_010312] KLA .94 .98 .94 1.08 1.23 1.32 1.16
ATP 1.04 .96 .59 .64 .59 .76 1.18
KLA/ATP 1.02 .84 .62 .64 .61 .89 1.36
Gnb3
KLA  ATP  ATP+KLA
 NM_013530 guanine nucleotide binding protein (G protein), beta 3 (Gnb3), mRNA [NM_013530] KLA .99 1.00 .98 1.03 .94 .99 .96
ATP 1.01 1.02 .97 .95 1.01 .97 .92
KLA/ATP .99 1.02 1.02 .98 .99 .85 .99
Gnb4
KLA  ATP  ATP+KLA
 AK165084 2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330002E21 product:guanine nucleotide binding protein, beta 4, full insert sequence [AK165084] KLA 4.61 4.10 4.23 2.41 2.25 1.59 .93
ATP 1.21 1.17 1.04 .81 2.92 1.50 1.03
KLA/ATP 5.86 6.56 3.60 1.68 5.62 3.00 1.37
Gnb4
KLA  ATP  ATP+KLA
 NM_013531 guanine nucleotide binding protein (G protein), beta 4 (Gnb4), mRNA [NM_013531] KLA 8.41 8.09 10.57 9.44 6.06 2.97 .92
ATP 1.07 1.04 1.09 .87 1.48 2.10 1.18
KLA/ATP 8.14 8.93 9.12 7.69 5.03 5.11 2.37
Gnb5
KLA  ATP  ATP+KLA
 NM_010313 guanine nucleotide binding protein (G protein), beta 5 (Gnb5), transcript variant 1, mRNA [NM_010313] KLA .68 .75 .67 .66 .53 .50 .65
ATP 1.03 1.08 1.09 1.14 .72 .54 .77
KLA/ATP .73 .70 .71 .73 .61 .65 .58
Gng10
KLA  ATP  ATP+KLA
 NM_025277 guanine nucleotide binding protein (G protein), gamma 10 (Gng10), mRNA [NM_025277] KLA .95 .95 .86 .83 .70 .53 .43
ATP .93 1.03 1.17 1.21 .97 .60 .52
KLA/ATP .84 .91 .93 .99 .79 .47 .24
Gng11
KLA  ATP  ATP+KLA
 NM_025331 guanine nucleotide binding protein (G protein), gamma 11 (Gng11), mRNA [NM_025331] KLA 1.30 1.26 1.44 1.54 1.26 1.42 1.90
ATP .88 .78 1.26 1.14 .90 .64 1.60
KLA/ATP 1.11 1.18 1.81 1.55 1.81 1.75 3.05
Gng12
KLA  ATP  ATP+KLA
 NM_025278 guanine nucleotide binding protein (G protein), gamma 12 (Gng12), mRNA [NM_025278] KLA 2.21 2.23 2.48 2.62 2.47 2.28 1.68
ATP 1.02 1.02 1.09 1.10 1.20 1.32 1.01
KLA/ATP 2.10 2.17 2.38 2.40 1.91 1.60 1.77
Gng13
KLA  ATP  ATP+KLA
 NM_022422 guanine nucleotide binding protein (G protein), gamma 13 (Gng13), mRNA [NM_022422] KLA 1.04 1.04 .94 1.00 1.00 1.05 .96
ATP 1.07 1.05 1.02 .94 .98 1.03 1.01
KLA/ATP 1.01 .99 1.05 1.01 1.01 .98 1.02
Gng2
KLA  ATP  ATP+KLA
 NM_010315 guanine nucleotide binding protein (G protein), gamma 2 (Gng2), transcript variant 1, mRNA [NM_010315] KLA .79 .81 .81 .82 .67 .57 .75
ATP 1.02 1.01 1.13 1.35 1.48 1.01 1.31
KLA/ATP .79 .86 .97 1.05 1.29 1.00 .84
Gng3
KLA  ATP  ATP+KLA
 NM_010316 guanine nucleotide binding protein (G protein), gamma 3 (Gng3), mRNA [NM_010316] KLA 1.00 .98 1.02 .95 .99 1.00 1.06
ATP .98 1.05 .99 1.03 1.05 1.03 .97
KLA/ATP 1.01 1.00 1.07 1.01 1.04 1.04 1.05
Gng4
KLA  ATP  ATP+KLA
 NM_010317 guanine nucleotide binding protein (G protein), gamma 4 (Gng4), mRNA [NM_010317] KLA 1.27 1.26 1.47 1.30 1.15 1.13 .82
ATP 1.05 .97 1.07 1.62 3.97 3.46 1.24
KLA/ATP 1.35 1.32 1.37 1.35 1.64 2.18 1.56
Gng5
KLA  ATP  ATP+KLA
 NM_010318 guanine nucleotide binding protein (G protein), gamma 5 (Gng5), mRNA [NM_010318] KLA .94 .84 .80 1.12 .98 1.11 1.29
ATP 1.07 1.01 1.07 1.05 1.17 1.52 1.01
KLA/ATP .83 .94 1.27 1.17 1.19 1.35 1.36
Gng7
KLA  ATP  ATP+KLA
 NM_001038655 guanine nucleotide binding protein (G protein), gamma 7 (Gng7), transcript variant 1, mRNA [NM_001038655] KLA .92 .96 .87 .91 .83 .98 .98
ATP 1.04 1.06 .98 .95 .81 .77 .75
KLA/ATP .97 .95 .81 .91 .79 .77 .81
Gng8
KLA  ATP  ATP+KLA
 NM_010320 guanine nucleotide binding protein (G protein), gamma 8 (Gng8), mRNA [NM_010320] KLA .93 .93 .95 .96 .90 .88 1.09
ATP .95 .90 1.01 .92 1.04 1.01 1.05
KLA/ATP .97 1.03 .99 .90 1.10 .99 1.04
Gngt1
KLA  ATP  ATP+KLA
 NM_010314 guanine nucleotide binding protein (G protein), gamma transducing activity polypeptide 1 (Gngt1), mRNA [NM_010314] KLA 1.06 .99 .95 .98 1.03 1.10 .98
ATP .96 1.02 1.03 1.03 .94 1.06 .95
KLA/ATP .98 1.03 1.04 1.04 1.01 1.03 1.01
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Itpr1
KLA  ATP  ATP+KLA
 NM_010585 inositol 1,4,5-triphosphate receptor 1 (Itpr1), mRNA [NM_010585] KLA 3.66 3.69 6.74 8.11 7.08 4.40 1.22
ATP 1.08 .95 1.19 .94 1.09 1.00 .68
KLA/ATP 3.48 3.58 5.86 6.03 4.01 2.31 .97
Itpr2
KLA  ATP  ATP+KLA
 NM_019923 inositol 1,4,5-triphosphate receptor 2 (Itpr2), transcript variant 1, mRNA [NM_019923] KLA 1.41 1.38 1.43 1.42 1.30 1.07 1.01
ATP 1.00 1.00 .97 .97 1.07 1.15 1.06
KLA/ATP 1.39 1.48 1.64 1.42 1.07 .83 .95
Itpr3
KLA  ATP  ATP+KLA
 NM_080553 inositol 1,4,5-triphosphate receptor 3 (Itpr3), mRNA [NM_080553] KLA .55 .51 .45 .41 .34 .34 .45
ATP 1.01 .92 1.02 .57 .46 .34 1.22
KLA/ATP .56 .48 .48 .29 .33 .27 .65
Jak2
KLA  ATP  ATP+KLA
 NM_008413 Janus kinase 2 (Jak2), transcript variant 1, mRNA [NM_008413] KLA 14.86 15.05 15.42 14.15 11.46 8.81 5.47
ATP .99 1.06 1.09 1.43 2.83 4.71 1.62
KLA/ATP 13.77 14.74 14.94 12.97 7.53 9.34 9.17
Kcnj12
KLA  ATP  ATP+KLA
 NM_010603 potassium inwardly-rectifying channel, subfamily J, member 12 (Kcnj12), mRNA [NM_010603] KLA .96 .98 .94 1.02 1.02 1.08 1.05
ATP 1.00 .93 1.05 1.08 1.31 1.08 1.00
KLA/ATP .95 .95 .93 1.02 1.14 1.04 1.04
Kcnj14
KLA  ATP  ATP+KLA
 NM_145963 potassium inwardly-rectifying channel, subfamily J, member 14 (Kcnj14), mRNA [NM_145963] KLA .98 .96 .97 1.02 1.03 .95 .97
ATP 1.09 1.05 1.03 .99 1.03 .94 .95
KLA/ATP 1.03 .99 .97 1.00 .97 .99 .96
Kcnj2
KLA  ATP  ATP+KLA
 NM_008425 potassium inwardly-rectifying channel, subfamily J, member 2 (Kcnj2), mRNA [NM_008425] KLA .68 .68 .77 .76 .61 .66 .91
ATP 1.11 1.38 1.52 1.39 .91 .83 .73
KLA/ATP .73 .79 1.08 1.15 .73 .65 .80
Kcnj3
KLA  ATP  ATP+KLA
 BC068167 potassium inwardly-rectifying channel, subfamily J, member 3, mRNA (cDNA clone MGC:92970 IMAGE:30543982), complete cds [BC068167] KLA .99 .97 1.01 .94 .97 .99 .99
ATP 1.06 1.01 1.03 .82 1.01 1.00 .94
KLA/ATP .98 .91 .99 .99 1.01 1.11 .97
Kcnj3
KLA  ATP  ATP+KLA
 NM_008426 potassium inwardly-rectifying channel, subfamily J, member 3 (Kcnj3), mRNA [NM_008426] KLA 1.05 .99 1.04 1.02 1.02 1.04 .94
ATP 1.00 1.01 1.02 .99 .96 1.03 1.04
KLA/ATP 1.00 .98 1.03 1.02 1.02 .96 1.06
Kcnj4
KLA  ATP  ATP+KLA
 NM_008427 potassium inwardly-rectifying channel, subfamily J, member 4 (Kcnj4), mRNA [NM_008427] KLA .94 .93 1.00 .93 .99 1.05 .96
ATP .95 1.01 .95 .99 1.05 .96 1.05
KLA/ATP .99 .97 .97 1.00 1.03 .99 .97
Kcnj6
KLA  ATP  ATP+KLA
 NM_001025585 potassium inwardly-rectifying channel, subfamily J, member 6 (Kcnj6), transcript variant Girk2B, mRNA [NM_001025585] KLA .97 .96 .95 .96 .98 .96 .95
ATP 1.00 .98 1.02 1.00 .98 .96 .97
KLA/ATP .98 .95 .99 .96 .98 .93 .96
Kcnj6
KLA  ATP  ATP+KLA
 NM_010606 potassium inwardly-rectifying channel, subfamily J, member 6 (Kcnj6), transcript variant Girk2A-1, mRNA [NM_010606] KLA .96 1.03 .97 .98 .97 .99 1.07
ATP 1.08 .99 .99 1.05 .96 1.04 .97
KLA/ATP 1.01 .92 1.03 1.03 1.04 1.03 1.08
Kcnq1
KLA  ATP  ATP+KLA
 NM_008434 potassium voltage-gated channel, subfamily Q, member 1 (Kcnq1), mRNA [NM_008434] KLA .80 .77 .67 .78 .65 .54 .42
ATP 1.06 .94 1.00 1.12 .97 .69 .60
KLA/ATP .75 .85 .83 .87 .70 .62 .56
Kcnq2
KLA  ATP  ATP+KLA
 NM_010611 potassium voltage-gated channel, subfamily Q, member 2 (Kcnq2), transcript variant 1, mRNA [NM_010611] KLA 1.05 1.03 1.00 .92 .93 1.10 1.00
ATP 1.00 1.00 .95 1.02 1.04 .95 1.00
KLA/ATP 1.00 .98 .98 1.05 1.01 1.04 1.03
Kcnq3
KLA  ATP  ATP+KLA
 NM_152923 potassium voltage-gated channel, subfamily Q, member 3 (Kcnq3), mRNA [NM_152923] KLA 1.00 .96 1.01 1.04 1.01 1.01 .99
ATP .98 1.00 1.06 .99 1.04 .98 1.01
KLA/ATP 1.04 1.02 1.02 .95 1.02 .89 .95
Kcnq4
KLA  ATP  ATP+KLA
 NM_001081142 potassium voltage-gated channel, subfamily Q, member 4 (Kcnq4), mRNA [NM_001081142] KLA .99 .98 .98 1.01 1.03 .96 1.09
ATP .93 .97 1.02 .99 1.07 1.01 1.11
KLA/ATP 1.00 1.07 .97 .80 1.05 1.04 1.04
Kcnq5
KLA  ATP  ATP+KLA
 AK147264 cDNA, RIKEN full-length enriched library, clone:M5C1004G17 product:potassium voltage-gated channel, subfamily Q, member 5, full insert sequence [AK147264] KLA .96 .97 .95 1.04 1.00 .96 .99
ATP 1.00 1.01 .99 .95 .99 .98 1.17
KLA/ATP .95 .97 1.01 .97 .93 .97 .96
Kcnq5
KLA  ATP  ATP+KLA
 NM_023872 potassium voltage-gated channel, subfamily Q, member 5 (Kcnq5), mRNA [NM_023872] KLA 1.06 .98 1.00 .98 .91 1.03 1.08
ATP 1.02 .99 .97 .96 1.00 .97 .98
KLA/ATP 1.07 1.02 .99 1.06 1.00 1.01 .99
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mm.13153
0
KLA  ATP  ATP+KLA
 161086915 Unknown KLA 1.00 1.07 1.14 1.08 .97 1.00 .93
ATP 1.04 .99 1.00 .95 .99 1.02 .90
KLA/ATP 1.08 1.18 1.14 1.16 1.04 1.06 1.08
Mm.15524
1
KLA  ATP  ATP+KLA
 41055979 Unknown KLA .94 1.05 1.06 1.03 1.07 .94 .97
ATP .99 1.01 .98 .91 1.02 1.04 .95
KLA/ATP 1.06 1.02 .98 .82 .98 .98 1.03
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.24060
7
KLA  ATP  ATP+KLA
 162951825 Unknown KLA .94 .96 .91 1.02 .90 .84 .97
ATP 1.08 1.01 1.08 .95 1.04 .89 .89
KLA/ATP .93 1.01 1.05 .92 .84 .88 .76
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.41137
KLA  ATP  ATP+KLA
 148747308 Unknown KLA 1.03 1.00 .95 .92 1.04 .98 .96
ATP 1.02 .98 .98 .90 .95 .92 1.07
KLA/ATP .91 .89 1.01 .95 1.00 .96 .99
Mm.44050
5
KLA  ATP  ATP+KLA
 84579905 Unknown KLA 1.03 .96 .90 1.03 .94 1.15 1.23
ATP .88 .91 1.15 1.18 1.17 1.31 1.02
KLA/ATP .87 .97 1.19 1.18 1.36 1.34 1.25
Mm.44160
1
KLA  ATP  ATP+KLA
 145966786 Unknown KLA 1.08 .94 1.01 .97 .79 .78 .71
ATP 1.09 .92 1.10 .75 .65 .92 .69
KLA/ATP 1.01 .92 1.16 .81 .69 .56 .63
Mm.4424
KLA  ATP  ATP+KLA
 110225367 Unknown KLA .99 .93 1.01 1.02 1.00 .92 1.00
ATP .98 1.03 3.11 1.13 1.19 1.03 1.11
KLA/ATP .95 .97 .97 .96 .93 1.01 .99
Mm.4951
KLA  ATP  ATP+KLA
 142354425 Unknown KLA .65 .72 .76 .68 .64 .73 .96
ATP 1.05 1.31 1.62 1.59 .95 .71 .77
KLA/ATP .68 .82 1.16 1.23 .86 .69 .83
Nras
KLA  ATP  ATP+KLA
 NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Plcb1
KLA  ATP  ATP+KLA
 AK129166 mRNA for mKIAA0581 protein [AK129166] KLA 1.02 .98 .91 .91 .92 .95 .89
ATP 1.03 1.02 1.02 1.01 .90 1.02 1.04
KLA/ATP .98 .97 .91 .93 .92 1.01 1.16
Plcb1
KLA  ATP  ATP+KLA
 NM_019677 phospholipase C, beta 1 (Plcb1), mRNA [NM_019677] KLA .99 .94 .95 .97 .93 .92 .91
ATP 1.00 .96 .99 .95 .99 1.03 .98
KLA/ATP .93 .96 .94 .93 .87 1.00 1.06
Plcb2
KLA  ATP  ATP+KLA
 NM_177568 phospholipase C, beta 2 (Plcb2), mRNA [NM_177568] KLA .70 .68 .64 .67 .65 .76 .88
ATP .95 .94 1.04 .94 .72 .57 1.19
KLA/ATP .69 .68 .72 .63 .65 .55 .70
Plcb3
KLA  ATP  ATP+KLA
 NM_008874 phospholipase C, beta 3 (Plcb3), mRNA [NM_008874] KLA 1.72 1.78 1.82 1.65 1.67 1.44 1.21
ATP .97 1.04 .81 .87 .78 .88 .94
KLA/ATP 1.69 1.89 1.44 1.66 1.12 .73 .93
Plcb4
KLA  ATP  ATP+KLA
 AK082509 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230058B11 product:unclassifiable, full insert sequence. [AK082509] KLA 1.06 1.03 .97 .98 1.02 1.01 .99
ATP .99 1.07 1.09 .95 .97 .97 1.02
KLA/ATP .98 1.00 1.03 .96 1.02 .91 .98
Plcb4
KLA  ATP  ATP+KLA
 NM_013829 phospholipase C, beta 4 (Plcb4), mRNA [NM_013829] KLA .88 .94 .81 .82 .81 .86 1.01
ATP 1.00 1.01 .92 .93 .88 .85 .89
KLA/ATP .97 .94 .78 .80 .78 .86 .97
Prkaca
KLA  ATP  ATP+KLA
 NM_008854 protein kinase, cAMP dependent, catalytic, alpha (Prkaca), mRNA [NM_008854] KLA .71 .74 .72 .70 .72 .84 .85
ATP 1.05 .98 .89 .92 .76 .60 1.02
KLA/ATP .79 .74 .55 .65 .60 .65 .93
Prkacb
KLA  ATP  ATP+KLA
 NM_011100 protein kinase, cAMP dependent, catalytic, beta (Prkacb), mRNA [NM_011100] KLA .69 .70 .66 .58 .51 .55 .59
ATP 1.02 1.19 .97 1.01 .69 .38 .56
KLA/ATP .72 .73 .57 .62 .47 .41 .45
Prkca
KLA  ATP  ATP+KLA
 NM_011101 protein kinase C, alpha (Prkca), mRNA [NM_011101] KLA 1.00 .96 .94 .95 .95 .89 .96
ATP 1.00 1.03 .91 .94 .82 .87 1.13
KLA/ATP 1.02 .95 .91 .86 .78 .84 .94
Prkcb1
KLA  ATP  ATP+KLA
 NM_008855 protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] KLA .92 .95 .93 .78 .77 1.08 1.83
ATP 1.03 1.12 1.09 1.23 .90 2.08 .96
KLA/ATP .98 .99 .82 .89 .62 1.01 1.08
Prkcc
KLA  ATP  ATP+KLA
 NM_011102 protein kinase C, gamma (Prkcc), mRNA [NM_011102] KLA 1.02 1.04 1.11 1.04 .96 1.02 1.05
ATP .98 .98 1.05 1.03 1.08 .96 .95
KLA/ATP 1.21 1.16 1.09 1.07 1.04 .98 .93
Prkx
KLA  ATP  ATP+KLA
 NM_016979 protein kinase, X-linked (Prkx), mRNA [NM_016979] KLA 3.61 3.79 4.67 4.66 4.85 4.19 1.43
ATP .98 .90 .63 .61 1.12 1.90 1.29
KLA/ATP 3.56 3.36 2.62 2.06 2.26 2.87 2.31
Slc18a3
KLA  ATP  ATP+KLA
 NM_021712 solute carrier family 18 (vesicular monoamine), member 3 (Slc18a3), mRNA [NM_021712] KLA .91 1.00 1.02 .99 1.01 1.07 1.16
ATP 1.02 1.08 1.01 1.07 1.09 1.05 1.07
KLA/ATP 1.02 .98 1.04 1.19 1.09 1.08 1.04
Slc5a7
KLA  ATP  ATP+KLA
 NM_022025 solute carrier family 5 (choline transporter), member 7 (Slc5a7), mRNA [NM_022025] KLA .97 .97 1.04 1.00 1.01 1.01 1.00
ATP .94 1.03 .99 .95 1.02 1.03 1.00
KLA/ATP .99 1.01 1.03 1.00 1.01 .96 .96